AKBA Akebia Therapeutics
- 1.3000
- +0.0600+4.84%
- 1.3100
- +0.0100+0.77%
Akebia Therapeutics News
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on...
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
Averoa Seeks EU Approval for Chronic Kidney Disease Drug
France-based Averoa filed a marketing authorization application to the European Medicines Agency for its AVA1014 drug to treat complications associated with chronic kidney disease. The biopharmaceutic
Express News | Akebia Therapeutics Inc: on April 15, Company and Sta Entered Into Amendment #2 to Supply Agreement
Express News | Akebia Therapeutics Inc - Amendment Amends the Volume-Based Pricing Structure Under the Supply Agreement
Express News | Akebia Therapeutics Inc - Term of Supply Agreement Is Extended for an Additional Five Years and Expires on April 2, 2029
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersIN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) share
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
12 Health Care Stocks Moving In Friday's Intraday Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASD
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Akebia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 200.11% HC Wainwright & Co. $5 → $6 Maintains Buy 03/15/2024 150.09% HC Wainwright & Co. → $5 R
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently 0.5% higher. Akebia Therapeutics (AKBA
Sector Update: Health Care
Health care stocks were mixed premarket Thursday with the Health Care Select Sector SPDR Fund (XLV) inactive and iShares Biotechnology ETF (IBB) recently up 0.5%. Akebia Therapeutics (AKBA) shares wer
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved
Trending Stocks Today: Avalo Therapeutics Surges 340% Pre-Market
March 28th - US stocks trending pre-market: Gainers: $Avalo Therapeutics(AVTX.US)$ surges 340% to $20.9 with a turnover of $19.54 million. $Kidpik(PIK.US)$ shoots up 63.91% to $5.36 with a turnover of
Express News | Akebia Therapeutics Shares Are Trading Higher After the FDA Approved Vafseo Tablets for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
Akebia Shares Rally Premarket After FDA Approves Vafseo
By Colin Kellaher Shares of Akebia Therapeutics rose sharply in premarket trading Thursday after the biopharmaceutical company won U.S. Food and Drug Administration approval of its Vafseo drug for di
Analysis
Price Target
No Data
